{"id":"NCT02063854","sponsor":"Takeda","briefTitle":"A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets","officialTitle":"A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-02","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2014-02-14","resultsPosted":"2017-02-23","lastUpdate":"2017-02-23"},"enrollment":871,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Involutional Osteoporosis"],"interventions":[{"type":"DRUG","name":"NE-58095 IR","otherNames":[]},{"type":"DRUG","name":"NE-58095 IR Placebo","otherNames":[]},{"type":"DRUG","name":"NE-58095 DR","otherNames":[]},{"type":"DRUG","name":"NE-58095 DR Placebo","otherNames":[]}],"arms":[{"label":"NE-58095 IR 2.5 mg Once Daily on Awakening","type":"ACTIVE_COMPARATOR"},{"label":"NE-58095 DR 25 mg Once Monthly on Awakening","type":"EXPERIMENTAL"},{"label":"NE-58095 DR 25 mg Once Monthly Following Breakfast","type":"EXPERIMENTAL"},{"label":"NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast","type":"EXPERIMENTAL"},{"label":"NE-58095 DR 37.5 mg Once Monthly on Awakening","type":"EXPERIMENTAL"},{"label":"NE-58095 DR 37.5 mg Once Monthly Following Breakfast","type":"EXPERIMENTAL"},{"label":"NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast","type":"EXPERIMENTAL"}],"summary":"The present phase II/III, multicenter, randomized, double-blind, parallel group comparative study is designed to evaluate the efficacy and safety of once-monthly oral administration of NE-58095 delayed release (DR) tablets for 12 months in participants with involutional osteoporosis. For this study, participants receiving oral NE-58095 immediate release (IR) 2.5 mg tablets once daily for 12 months are set as the control group.","primaryOutcome":{"measure":"Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study","timeFrame":"Baseline and End of Study (up to Month 12)","effectByArm":[{"arm":"NE-58095 IR 2.5 mg Once Daily on Awakening","deltaMin":5.07,"sd":4.749},{"arm":"NE-58095 DR 25 mg Once Monthly Following Breakfast","deltaMin":3.36,"sd":4.332},{"arm":"NE-58095 DR 37.5 mg Once Monthly Following Breakfast","deltaMin":4.11,"sd":4.654}],"pValues":[{"comp":"OG000 vs OG002","p":"0.1346"},{"comp":"OG000 vs OG001","p":"0.6711"},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":199},"commonTop":["Nasopharyngitis","Abdominal discomfort","Fall","Constipation","Contusion"]}}